source
- Beyond GLP-1s: Companies eye new obesity drug mechanisms as efficacy plateausThe obesity drug market continues to expand, with GLP-1 therapies growing from about $5.5 billion in 2023 to over $55 billion projected for 2033. These agents are used for weight loss, diabetes and…
- Novartis and Bristol Myers pause autoimmune CAR-T trials after serious safety eventsNovartis and Bristol Myers Squibb announced the suspension of several autoimmune CAR‑T studies after encountering serious safety problems. In Novartis' trials, three participants died from a severe…